Seeking Alpha

Targacept (TRGT) -10.3% premarket after announcing revised top-line results from its exploratory...

Targacept (TRGT) -10.3% premarket after announcing revised top-line results from its exploratory Phase 2 study of TC-6987 in asthma show it no longer achieves protocol-defined success criteria on the primary endpoint of Forced Expiratory Volume.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)